Corporate-VC deal dips into NIH

Most venture-backed startups are bets on the science, but in forming GenVec, Hillman Medical Ventures and its partners are betting on the scientist.

Ronald Crystal, a founder and chief scientific advisor of the company, is leaving the National Institutes of Health with nothing but his know-how in developing in vivo gene therapy. The company plans to develop drugs for cystic fibrosis, cancer and other pulmonary diseases...